Innocan Pharma (CSE: INNO- OTC: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has hit a major milestone in the development of CLX Therapy which holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.
Bincovich telling Proactive they have been able to successfully complete a large-scale production of exosomes. The company is still in the development stage of the CLX platform but this step shows part of the path to commercialization.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE